Minerva Neurosciences reported $0 in Sales Revenues for its fourth fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Sales Change
Acadia Pharmaceuticals ACAD:US USD 130.71M 3.85M
Adma Biologics ADMA:US USD 41.09M 7.18M
ALKERMES ALKS:US USD 252.36M 23.86M
AstraZeneca AZN:LN USD 10.98B 211M
Biocryst Pharmaceuticals BCRX:US USD 75.83M 10.3M
Bristol Myers Squibb BMY:US USD 11.22B 669M
Dynavax Technologies DVAX:US USD 167.74M 88.73M
Eli Lilly And LLY:US USD 6.94B 453.6M
Esperion Therapeutics ESPR:US USD 18.98M 139K
GlaxoSmithKline GSK:LN GBP 782.9B 90B
Halozyme Therapeutics HALO:US USD 208.98M 56.61M
IONIS PHARMACEUT IONS:US USD 159.77M 25.98M
Johnson & Johnson JNJ:US USD 23.79B 229M
Marinus Pharmaceuticals MRNS:US USD 2.34M 550K
Merk MRK:US USD 14.96B 366M
Neurocrine Biosciences NBIX:US USD 387.9M 9.7M
Novartis NOVN:VX USD 12.84B 243M
Novavax NVAX:US USD 734.58M 548.65M
Pfizer PFE:US USD 22.64B 5.1B
Roche Holding ROG:VX CHF 32.3B 207M
Takeda 4502:JP JPY 1T 29.84B
Vanda Pharmaceuticals VNDA:US USD 130.64M 1.86M